Haploidentical stem cell transplantation in a boy with chronic granulomatous disease

Main Article Content

A. Regueiro-García
S. Farina-Nogueira
J.Á. Porto-Arceo
J.M. Couselo-Sánchez

Keywords

Chronic granulomatous disease, Haploidentical, Hematopoietic stem cell transplantation, Immunologic deficiency syndromes, Treosulfan

Abstract

Chronic granulomatous disease is a primary immunodeficiency caused by mutations in any one of the five components of the NADPH oxidase in phagocytic leucocytes. This causes impaired microbial killing, which leads to severe life-threatening bacterial and fungal infections. Currently, allogenic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for chronic granulomatous disease, although gene therapy may provide a new therapeutic option for the treatment of patients with CGD. Haploidentical HSCT provides a potentially curative treatment option for patients who lack a suitably HLA-matched donor, but only a few cases have been reported in the literature. Herein, we report a boy with X-linked chronic granulomatous disease treated successfully by haploidentical HSCT with post-transplant cyclophosphamide using a treosulfan-based conditioning regimen.

Abstract 62 | PDF Downloads 62

References

1. Goldblatt D. Recent advances in chronic granulomatous disease. J Infect. 2014;69:S32-5.

2. van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bematowska E, Corbeel L, et al. Chronic granulomatous disease: the European experience. PLoS ONE. 2009;4:e5234.

3. Cole T, McKendrick F, Titman P, Cant AJ, Pearce MS, Cale CM, et al. Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant. J Clin Immunol. 2013;33:8-13.

4. Cole T, Mark S, Pearce MS, Cant AJ, Cale CM, Glodblatt D, et al. Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2013;132:1150-5.

5. Soncini E, Slatter MA, Jones LB, Hughes S, Hodges S, Flood TJ, et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol. 2009;145:73-83.

6. Calvino˜ MC, Maldonado MS, Otheo E, Munoz ˜ A, Couselo JM, Burgaleta C. Bone marrow transplantation in chronic granulomatous disease. Eur J Pediatr. 1996;155:877-9.

7. Klein OR, Chen AR, Gamper C, Loeb D, Zambidis E, Llosa N, et al. Alternative donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for non-malignant disorders. Biol Blood Marrow Transplant. 2016;22:895-901.

8. Hoenig M, Niehues T, Siepermann K, Jacobsen EM, Schütz C, Furlan I, et al. Successful HLA haploidentical hematopoietic SCT in chronic granulomatous disease. Bone Marrow Transplant. 2014;49:1337-8.

9. Zhou L, Dong LJ, Gao ZY, Yu XJ, Lu DP. Haploidentical hematopoietic stem cell transplantation for a case with X-linked chronic granulomatous disease. Pediatr Transplant. 2017;21:e12861.

10. Parta M, Hilligoss D, Kelly C, Kwatemaa N, Theobald N, Malech H, et al. Haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in a patient with chronic granulomatous disease and active infection: a first report. J Clin Immunol. 2015;35:675-80.

11. Morillo-Gutierrez B, Beier R, Rao K, Burroughs L, Schulz A, Ewins AM, et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood. 2016;128:440-8.

12. Jurik MK, Ghimire S, Ogonek J, Weissinger EM, Holler E, van Rood JJ, et al. Milestones of hematopoietic stem cell transplantation --- from first human studies to current developments. Front Immunol. 2016;7:470.

13. O’Donell PV, Eapen M, Horowitz MM, Logan BR, DiGlio A, Brunstein C, et al. Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-myeloablative conditioning: a matched-pair analysis. Bone Marrow Transplant. 2016;51:1599-601.

14. Eapen M, Logan BR, Horowitz M, Zhong X, Perales M-A, Lee SJ, et al. Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. J Clin Oncol. 2015;33:364-9.

15. Baron F, Mohty M, Blaise D, Socié G, Labopin M, Esteve J, et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:224-34.

16. Xu X, Tailor CS, Grunebaum E. Gene therapy for primary immune deficiencies: a Canadian perspective. Allergy Asthma Clin Immunol. 2017;13:14.